BRIEF published on 12/11/2025 at 23:05, 1 month 26 days ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 1 month 26 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 1 month 26 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 2 months 18 days ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 2 months 18 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 2 months 18 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 2 months 24 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 2 months 24 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 2 months 24 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 3 months 28 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 02/07/2026 at 01:00, 14 hours 41 minutes ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 16 hours 31 minutes ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 17 hours 40 minutes ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 2 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/06/2026 at 19:25, 20 hours 15 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 21 hours 48 minutes ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 17:40, 22 hours 1 minute ago Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.01.26.
Published on 02/06/2026 at 16:55, 22 hours 45 minutes ago GAC MPV Serves as Official Reception Fleet for APEC China 2026, Demonstrating the Strength of Chinese Manufacturing
Published on 02/06/2026 at 15:25, 1 day ago CES 2026 Innovation Award Honoree iGarden M1 Pro Max Launches as World's First Bionic Dual-Vision Pool Cleaner
Published on 02/06/2026 at 18:22, 21 hours 18 minutes ago Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 21 hours 18 minutes ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 23 hours 39 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 23 hours 39 minutes ago Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 1 day 7 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026
